GlassScriptPhysician profile
David A Dudley
NPI 1154331841
$1,368.23
in general payments reported to CMS, 2019-2025
33 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $65.01 · 2021: $369 · 2022: $129 · 2023: $169 · 2024: $258 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.85 | 2020-2025 | Mavyret |
| Otsuka America Pharmaceutical, INC. | $112.03 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $101.49 | 2021-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Amgen INC. | $101.22 | 2020-2023 | Repatha, Otezla |
| Daiichi Sankyo INC. | $78.64 | 2021-2024 | Injectafer |
| Novo Nordisk INC | $71.53 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $44.58 | 2023-2025 | |
| Lilly USA, LLC | $43.29 | 2022-2025 | Jardiance, Mounjaro |
| Biogen, INC. | $32.55 | 2021 | |
| Ardelyx, INC. | $30.91 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.64 | 2023-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $27.20 | 2022 | |
| Abbott Laboratories | $22.56 | 2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $19.54 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $19.37 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.37 | 2024 | Watchman Flx |
| Kyowa Kirin, INC. | $18.87 | 2024 | Crysvita |
| Ironwood Pharmaceuticals, INC | $18.05 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $17.96 | 2025 | Iqirvo |
| Eisai INC. | $16.08 | 2025 | |
| Aimmune Therapeutics, INC. | $15.91 | 2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $14.98 | 2025 | Hetlioz, Fanapt |
| Insulet Corporation | $14.48 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.11 | 2023 | Spiriva Respimat |
| Genzyme Corporation | $14.10 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $13.96 | 2022 | |
| Celgene Corporation | $13.95 | 2021 | |
| Convatec INC. | $13.81 | 2025 | |
| Organon LLC | $13.66 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.58 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.53 | 2025 | Airsupra |
| Radius Health, INC. | $11.67 | 2020 | |
| Mayne Pharma Commercial LLC | $9.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dudley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.